system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: BACKGROUND, RESULTS. Meshes: Animals, Blotting, Western, Cell Line, Disease Models, Animal, Enzyme-Linked Immunosorbent Assay, Humans, Interleukin-1beta, Male, Neuralgia, Polymerase Chain Reaction, RNA, Small Interfering, Rats, Rats, Sprague-Dawley, Toll-Like Receptor 4, Tumor Necrosis Factor-alpha.
user
Does intrathecal siRNA against Toll-like receptor 4 reduce nociception in a rat model of neuropathic pain? Context: Neuropathic pain is characterized by hyperalgesia, allodynia and spontaneous pain. It often occurs as a result of injury to peripheral nerves, dorsal root ganglions (DRG), spinal cord, or brain. Recent studies have suggested that Toll-like receptor 4 (TLR4) might play a role in neuropathic pain. In this study, we investigated the role of TLR4 in a rat chronic constriction injury (CCI) model and explored the feasibility of treating neuropathic pain by inhibiting TLR4. Our results demonstrated that intrathecal siRNA-mediated suppression of TLR4 attenuated CCI-induced mechanical allodynia and thermal hyperalgesia through inhibiting the activation of NF-kappaB p65 and production of proinflammatory cytokines (e.g., TNF-alpha and IL-1 beta).
assistant
These findings suggest that suppression of TLR4 mediated by intrathecally administered siRNA may be a new strategy for the treatment of neuropathic pain. Final Decision: yes